Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-grass pollen allergen extract, marketed under the brand name Oralair, is a sublingual immunotherapy (SLIT) tablet containing standardized allergen extracts from five grass species: orchard (*Dactylis glomerata*), meadow (*Poa pratensis*), perennial rye (*Lolium perenne*), sweet vernal (*Anthoxanthum odoratum*), and timothy (*Phleum pratense*). Developed by Stallergenes S.A., it is formulated at 300 index of reactivity (IR) and is administered once daily sublingually in a pre- and co-seasonal regimen. The drug acts by inducing immunological tolerance to grass pollen allergens, thereby modulating the immune system's IgE-mediated allergic response. It is indicated for the treatment of moderate to severe seasonal grass pollen allergic rhinitis and rhinoconjunctivitis in patients aged 5 to 50 years and has been approved in over 30 countries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mixed grass pollens allergen extract.